- Q1 2024 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024$43.9 (-10.06%)Earnings
- Q4 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024$69.35 (-3.32%)Earnings
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare C-Suite Unscripted Conference TranscriptJan 04, 2024
- Apellis Pharmaceuticals Inc to Discuss the CHMP Trend Vote TranscriptDec 14, 2023
- Apellis Pharmaceuticals Inc at Evercore ISI HealthCONx Conference TranscriptNov 28, 2023
- Q3 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 01, 2023$49.9 (+2.55%)Earnings
- Apellis Pharmaceuticals Inc at Robert W Baird Global Healthcare Conference TranscriptSep 12, 2023
- Apellis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Apellis Pharmaceuticals Inc at Wells Fargo Healthcare Conference TranscriptSep 08, 2023
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptJul 31, 2023$25.75 (-19.58%)Earnings
- Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2023$84.37 (-0.76%)Earnings
- Apellis Pharmaceuticals Inc SYFOVRE FDA Approval Call TranscriptFeb 17, 2023
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Apellis Pharmaceuticals Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2022$47.62 (-5.55%)Earnings
- Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptSep 16, 2022
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 07, 2022
- Apellis Pharmaceuticals Inc Corporate Call TranscriptAug 24, 2022
- Q2 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2022$62.33 (-1.58%)Earnings
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Apellis Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Apellis Pharmaceuticals Inc at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2022$45.95 (+3.00%)Earnings
- Apellis Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Apellis Pharmaceuticals Inc DERBY and OAKS 18 Month Data Conference Call TranscriptMar 16, 2022
- Apellis Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) TranscriptMar 09, 2022
- Q4 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 28, 2022$42.53Earnings
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Apellis Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 10, 2021
- Q3 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 08, 2021$33.69 (-1.35%)Earnings
- Apellis Pharmaceuticals Inc Announces results from Phase 3Â DERBY and OAKS TranscriptSep 09, 2021
- Q2 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2021$62 (-2.18%)Earnings
- Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually TranscriptJun 30, 2021
- Apellis Pharmaceuticals Inc at Bank of America NAPA Healthcare Conference TranscriptJun 16, 2021
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Apellis Pharmaceuticals Inc EMPAVELI FDA Approval Call TranscriptMay 17, 2021
- Q1 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptApr 28, 2021$45.3 (-0.33%)Earnings
- Q4 2020 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 25, 2021$45.05 (-2.49%)Earnings
- Apellis Pharmaceuticals Inc Virtual Investorm Meeting - Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) TranscriptJan 28, 2021
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Apellis Pharmaceuticals Inc Sobi Strategic Collaboration Conference Call TranscriptOct 27, 2020
- Apellis Pharmaceuticals Inc The Evolution of Complement Targeted Therapies Panel at Stifel Immunology & Inflammation Summit (Virtual) TranscriptOct 01, 2020
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) - Fireside Chat TranscriptSep 10, 2020
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- Apellis Pharmaceuticals Inc to Discuss Phase 3 PEGASUS Study Results - Conference Call TranscriptJun 12, 2020
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Apellis Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Apellis Pharmaceuticals, Inc. - Special Call TranscriptJan 07, 2020
- Apellis Pharmaceuticals Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference TranscriptSep 05, 2019
Apellis Pharmaceuticals Inc SYFOVRE FDA Approval Call Transcript
Thank you for standing by, and welcome to the Apellis SYFOVRE FDA approval conference call. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to hand the conference over to your host, Meredith Kaya. Please begin.
Thank you for joining us today to discuss the FDA approval of intravitreal pegcetacoplan, now with the brand name SYFOVRE, as the first and only treatment for geographic atrophy, or GA.
With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Medical Officer, Dr. Caroline Baumal; and Chief Commercial Officer, Adam Townsend. Tim Sullivan, Chief Financial Officer, will be available for the Q&A.
Before we begin, I would like to point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)